7月14日 - ** 肿瘤生物技术公司Crescent Biopharma的 CBIO.O 股票在盘后交易中下跌1%，报15.15美元
** 总部位于马萨诸塞州沃尔瑟姆的CBIO开始发行股票和预先注资认股权证 (link)；交易规模未披露
** 根据向美国证券交易委员会（SEC）提交的文件，CBIO还估计截至6月底其现金及现金等价物约为1.716亿美元 (link)
** 根据招股说明书，该公司计划将募集资金净额用于资助CR-001、CR-002和CR-003的临床开发，以及继续开展临床前项目的研发等用途 (link)
** 杰富瑞（Jefferies）、道明考恩（TD Cowen）、古根海姆（Guggenheim）和坎托菲茨杰拉德（Cantor Fitzgerald）担任联合簿记管理人
** CBIO流通股约为2760万股，市值约为4.2亿美元
** 周二收盘时，股价下跌2.5%至15.31美元，使年初至今的涨幅收窄至29%
** 据伦敦证券交易所集团（LSEG）数据显示，9位分析师中有8位给予该股“强烈买入”或“买入”评级，1位给予“持有”评级；目标价中位数为30美元
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.